NEW YORK, March 27, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been
filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to
request that the court appoint you as lead plaintiff.
Vale S.A. (NYSE: VALE)
Class Period: April 11, 2017 to January 28, 2019
Lead Plaintiff Deadline: March 29, 2019
During the class period, Vale S.A. allegedly made materially false and/or misleading statements and/or failed to
disclose that: (i) Vale had failed to adequately assess the risk and damage potential of a dam breach at its Feijão iron ore mine
especially in light of its experience in 2015; (ii) Vale’s programs to mitigate health and safety incidents were inadequate; (iii)
Defendants failed to disclose that Vale’s auditor was not independent, as required under Brazilian mining law; (iv) Defendants
failed to disclose that an internal report commissioned by Vale in 2018 to assess the stability of the tailings dam raised concerns
over its drainage and monitoring systems; (v) Defendants failed to disclose the existence of information that the dam was at risk
of "liquefaction,” the same issue that led to the 2015 collapse of the Samarco dam; and (vi) as a result, Vale’s public statements
were materially false and misleading at all relevant times.
Get additional information about the VALE lawsuit: http://www.kleinstocklaw.com/pslra-1/vale-s-a-loss-submission-form?wire=3
Bristow Group Inc. (NYSE: BRS)
Class Period: February 8, 2018 to February 12, 2019
Lead Plaintiff Deadline: April 15, 2019
According to the complaint, Bristow Group Inc. allegedly made materially false and/or misleading statements
and/or failed to disclose that: (1) Bristow lacked adequate monitoring processes related to non-financial covenants within its
secured financing and lease agreements; (2) Bristow could not reasonably assure compliance with certain non-financial covenants;
(3) Bristow was reasonably likely to breach certain agreements; (4) Bristow had understated its short-term debt; (5) the required
corrections would materially impact financial statements; (6) there was a material weakness in Bristow’s internal controls over
financial reporting; and (7) as a result of the foregoing, defendants’ positive statements about Bristow’s business, operations,
and prospects were materially misleading and/or lacked a reasonable basis.
Get additional information about the BRS lawsuit: http://www.kleinstocklaw.com/pslra-1/bristow-group-inc-loss-submission-form?wire=3
Conduent Incorporated (NYSE: CNDT)
Class Period: February 21, 2018 to November 6, 2018
Lead Plaintiff Deadline: May 7, 2019
The complaint alleges that by February 2018, defendants began to represent to investors that Conduent had exited
the transformation phase and had cured inefficiencies caused by operating on multiple information resource platforms. However, as
demonstrated by defendants’ admissions on November 7, 2018, those representations were false, and Conduent remained mired in
inadequate technology and third-party agreements that it had been saddled with upon its divestiture from Xerox. During a
November 7, 2018 conference call, CEO Ashok Vemuri stated “we have had continued suboptimal performance from an inherited legacy
technology vendor. The performance issues stem from the vendors inability to deliver on service level agreements, lack of
responsiveness to Conduent’s needs, and poorly structured contracts which we inherited.” Vemuri also noted that an “outdated and
historically under-invested legacy IT infrastructure has caused major disruptions to our operations and impacted client and
delivery performance.”
Get additional information about the CNDT lawsuit: http://www.kleinstocklaw.com/pslra-1/conduent-incorporated-loss-submission-form?wire=3
Corbus Pharmaceuticals Holdings, Inc. (NASDAQGM: CRBP)
Class Period: November 14, 2016 to February 28, 2019
Lead Plaintiff Deadline: May 13, 2019
The complaint alleges that throughout the class period Corbus Pharmaceuticals Holdings, Inc. made materially
false and/or misleading statements and/or failed to disclose that: (1) Corbus improperly changed the primary efficacy endpoint for
the clinical study of its drug candidate, Lenabasum, after the results were unblinded to Corbus; (2) Corbus reported a one-sided p
value, not the traditional two-sided p value normally reported in clinical trials, in an effort to conceal the fact that the study
results did not have statistical significance; and (3) as a result, Corbus’ public statements were materially false and misleading
at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
Get additional information about the CRBP lawsuit: http://www.kleinstocklaw.com/pslra-1/corbus-pharmaceutical-holdings-inc-loss-submission-form?wire=3
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or
obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J.
Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud
throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
